Expanded cohort results from CheckMate 016: a Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC) (#199)
Hans J Hammers
1
,
Elizabeth R Plimack
2
,
Jeffrey R Infante
3
,
Brian I Rini
4
,
David F McDermott
5
,
Marc S Ernstoff
6
,
Martin H Voss
6
,
Padmanee Sharma
7
,
Sumanta K Pal
8
,
Albiruni Razak
9
,
Christian Kollmannsberger
10
,
Daniel YC Heng
11
,
Jennifer Spratlin
12
,
Yun Shen
13
,
Paul Gagnier
13
,
Asim Amin
14
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
- Fox Chase Cancer Centre, Philadelphia, PA, USA
- Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN, USA
- Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
- Beth Israel Deaconess Medical Center, Boston, MA, USA
- Memorial Sloan-Kettering Cancer Centre, New York, NY, USA
- MD Anderson Cancer Center, University of Texas, Houston, TX, USA
- City of Hope Comprehensive Cancer Center, Duarte, CA, USA
- Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
- British Columbia Cancer Agency, Vancouver, British Columbia, Canada
- Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada
- Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
- Bristol-Myers Squibb, Princeton, NJ, USA
- Levine Cancer Institute, Charlotte, NC, USA